quinoxalines has been researched along with Atherosclerotic Parkinsonism in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (90.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| An, H; Bao, Y; Huang, D; Shen, N; Wang, K; Yang, J; Yu, F; Zeng, X; Zheng, L; Zhou, W | 1 |
| Bernardi, G; Calabresi, P; Mercuri, NB; Sancesario, G | 1 |
| Greenamyre, JT | 1 |
| Anzilotti, KF; Jackson, PF; Rissolo, KC; Stauch Slusher, B | 1 |
| Heneka, MT; Klockgether, T; Kunow, M; Löschmann, PA; Schulz, JB; Wachtel, H; Wüllner, U | 1 |
| Marin, C; Tolosa, E | 1 |
| Kunow, M; Löschmann, PA; Wachtel, H | 2 |
| Gash, DM; Greenamyre, JT; Honoré, T; Klockgether, T; Kurlan, R; Turski, L; Zhang, ZM | 1 |
| Honoré, T; Jähnig, P; Jenner, P; Kunow, M; Lange, KW; Löschmann, PA; Marsden, CD; Rettig, KJ; Turski, L; Wachtel, H | 1 |
1 review(s) available for quinoxalines and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Dopamine Agents; Drug Evaluation, Preclinical; Drug Synergism; Drug Tolerance; Excitatory Amino Acid Antagonists; Glutamates; Glutamic Acid; Haplorhini; Humans; Mice; MPTP Poisoning; Oxidopamine; Parkinson Disease; Parkinson Disease, Secondary; Quinoxalines; Rats; Receptors, Dopamine; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate; Synaptic Transmission | 1993 |
9 other study(ies) available for quinoxalines and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Benefits of Iron Chelators in the Treatment of Parkinson's Disease.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Deferoxamine; Dopaminergic Neurons; Ferric Compounds; Ferroptosis; Humans; Iron Chelating Agents; Iron Overload; Nerve Growth Factor; Neuroprotective Agents; Parkinson Disease, Secondary; Quaternary Ammonium Compounds; Quinoxalines; Rats; Reactive Oxygen Species; Spiro Compounds | 2021 |
Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 6-Cyano-7-nitroquinoxaline-2,3-dione; Action Potentials; Animals; Corpus Striatum; Denervation; Dopamine; Dopamine Agents; Ergolines; Male; Oxidopamine; Parkinson Disease, Secondary; Quinoxalines; Quinpirole; Rats; Rats, Wistar; Substantia Nigra; Synaptic Membranes; Tetrodotoxin | 1993 |
Centrally-administered AMPA antagonists increase locomotion in parkinsonian rats.
Topics: Animals; Anti-Anxiety Agents; Benzodiazepines; Excitatory Amino Acid Antagonists; Male; Mesencephalon; Microinjections; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Substantia Nigra | 1995 |
Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Dopamine Agonists; Drug Interactions; Excitatory Amino Acid Antagonists; Male; Oxidopamine; Parkinson Disease, Secondary; Quinoxalines; Rats; Rats, Wistar; Receptors, AMPA; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Rotation; Stereotyped Behavior | 1997 |
Glutamate receptor-mediated mechanisms in levodopa-induced motor fluctuations in an experimental model of parkinsonism.
Topics: Animals; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Levodopa; Male; Parkinson Disease, Secondary; Piperazines; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Rotation; Stereotyped Behavior; Time Factors | 1999 |
NBQX (6-nitro-sulfamoyl-benzo-quinoxaline-dione) and CPP (3-carboxy-piperazin-propyl phosphonic acid) potentiate dopamine agonist induced rotations in substantia nigra lesioned rats.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amphetamine; Animals; Apomorphine; Dopamine Agents; Drug Synergism; Ibotenic Acid; Lisuride; Male; Neurons; Oxidopamine; Parkinson Disease, Secondary; Piperazines; Quinoxalines; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Stereotyped Behavior; Substantia Nigra; Sympathectomy, Chemical | 1992 |
Synergism of NBQX with dopamine agonists in the 6-OHDA rat model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Drug Synergism; Lisuride; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Quinoxalines; Rats; Rats, Wistar; Stereotaxic Techniques; Substantia Nigra | 1992 |
The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys.
Topics: Animals; Dopamine; Female; Globus Pallidus; Levodopa; Macaca mulatta; MPTP Poisoning; Parkinson Disease, Secondary; Quinoxalines; Rats; Receptors, AMPA; Receptors, Neurotransmitter; Synaptic Transmission | 1991 |
Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-dopa in models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analysis of Variance; Animals; Callithrix; Disease Models, Animal; Drug Synergism; Ibotenic Acid; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Piperazines; Quinoxalines; Rats; Rats, Inbred Strains; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 1991 |